SL Science Seeks FDA Orphan Drug Status for Gamma Delta T Cell Therapy in Glioblastoma
I'm LongbridgeAI, I can summarize articles.SL Science Holding Ltd announced it submitted an Orphan Drug Designation request to the FDA for its Vdelta2+ Gamma Delta T cell therapy targeting glioblastoma multiforme. The FDA acknowledged receipt on July 10, 2026, following initial submission in March. This marks a key regulatory milestone for the company's brain cancer program, leveraging proprietary technology licensed from JY BioMed to address unmet needs in aggressive solid tumors.
The latest update is out from SL Science Holding Ltd ( (SLBT) ).
On July 10, 2026, SL Science Holding Limited reported that it has submitted an Orphan Drug Designation request to the U.S. Food and Drug Administration for its Vdelta2+ Gamma Delta T cell therapy targeting glioblastoma multiforme. The FDA’s Office of Orphan Products Development acknowledged receipt of the application, marking a key regulatory milestone for the company’s brain cancer program, with the request initially received by the agency on March 30, 2026.
The company’s Gamma Delta T cell platform is designed to attack tumor cells without relying on major histocompatibility complex presentation, aiming to overcome tumor heterogeneity and immune evasion in solid tumors. SL Science and JY BioMed researchers will also showcase preclinical data on intracranial γδ T cell therapy eliminating glioblastoma at the World Congress of Basic and Clinical Pharmacology 2026 in Melbourne, underscoring growing international recognition of the technology and its potential to address a critical unmet need in aggressive brain cancers.
More about SL Science Holding Ltd
SL Science Holding Limited is a Taiwan-headquartered biomedical company focused on innovative cellular and gene therapies for cancer and regenerative medicine. Leveraging proprietary Gamma Delta T cell technology licensed from JY BioMed, the company is developing treatments for solid tumors, including pancreatic and brain cancers, aiming to establish a strong position in the immuno-oncology segment of the biopharmaceutical industry.
SL Science seeks to use immune cell technologies to target hard-to-treat malignancies and address major unmet medical needs. By advancing differentiated cell therapy platforms that operate independently of traditional MHC presentation, the company is targeting tumor heterogeneity and immune evasion, positioning itself as a contender in next-generation cell therapy for solid tumors.
Average Trading Volume: 2,529,624
Current Market Cap: $2.56B
For a thorough assessment of SLBT stock, go to TipRanks’ Stock Analysis page.